Flagship-backed Kaleido raises $101M series C round

Microbiome company Kaleido Biosciences Inc. (Bedford, Mass.) raised $101 million in a series C round. Founding investor Flagship Pioneering participated, as did several

Read the full 238 word article

User Sign In